Key result
Doxorubicin in older non-Hodgkin lymphoma patients is linked to cardiotoxicity manifesting as LV dysfunction.
Highlights the challenges and risks of doxorubicin-induced cardiotoxicity in elderly patients with non-Hodgkin's lymphoma, a population often underrepresented in clinical trials.
May warrant cardiotoxicity monitoring in older non-Hodgkin lymphoma patients on doxorubicin; leaves open optimal prevention strategies in this underrepresented group.
Non-Hodgkin's lymphoma is a frequent disease in older patients, and at least half of non-Hodgkin's lymphoma diagnoses occur in patients older than 65 years. 1 This diagnosis presents special challenges in the older population because of pre-existing comorbidities, changes in drug pharmacokinetics, and poorer response rates and other outcomes.In addition, the lack of enrollment of older patients with existing comorbidities, such as cardiac disease, onto clinical trials has limited the accumulation of evidence-based clinical knowledge. 2nthracycline-based chemotherapy improves survival in multiple solid and hematologic malignancies.Doxorubicin is the anthracycline used most frequently in the treatment of diffuse large B-cell lymphoma as part of the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen, with or without rituximab (R-CHOP).The use of doxorubicin is associated with, and often limited by, a risk of cardiotoxicity manifested by left ventricular dysfunction.
No takes yet. Share an insight, caveat, or question.
Carver et al. (2008) conducted a review in Non-Hodgkin's lymphoma. Doxorubicin was evaluated on Cardiotoxicity manifested by left ventricular dysfunction. Doxorubicin use in older patients with non-Hodgkin's lymphoma is associated with a risk of cardiotoxicity manifested by left ventricular dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: